
    
      Study participants will be randomized to receive either 3 doses of a commercially available
      Oral Poliovirus Vaccine (OPV), or 1 dose of Sanofi Pasteur's injectable Inactivated
      Poliovirus Vaccine IMOVAX Polio (IPV) followed by 2 doses of OPV, or 2 doses of IPV followed
      by 1 dose of OPV.

      These vaccines will be administered at 2, 3 and 4 months of age as primary vaccination for
      the prevention of poliomyelitis. Participants will be followed up through their 18th- to
      19th-month birthday.
    
  